Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
IDGX On Other Exchanges
Symbol
Exchange
NASDAQ GM
All times are local (Market data is delayed by at least 15 minutes).

altheadx inc (IDGX) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
12.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALTHEADX INC (IDGX)

Related News

No related news articles were found.

altheadx inc (IDGX) Related Businessweek News

No Related Businessweek News Found

altheadx inc (IDGX) Details

AltheaDx, Inc. operates as a molecular diagnostics company that specializes in the field of pharmacogenetics in the United States. The company’s algorithm-based bioinformatic platform and pharmacogenetics (PGx) product testing portfolio serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen, and other key factors. It designs IDgenetix, a PGx testing portfolio that enables healthcare providers to make timely and evidence-based decisions. The company also offers research and development services that provide a start-to-finish suite of tools focused on molecular biomarker discovery, assay development, assay validation, and prospective/retrospective clinical trial testing in support of companion diagnostic development and commercialization primarily in oncology to various biopharmaceutical partners. Its testing portfolio addresses various prevalent clinical conditions, including cardiovascular disease, neuropsychiatric disorders, and pain. The company serves long-term and post-acute care facilities, pharmaceutical companies, government facilities, integrated delivery networks, and managed care organizations, as well as physicians. AltheaDx, Inc. was founded in 1998 and is based in San Diego, California.

81 Employees
Last Reported Date: 01/23/15
Founded in 1998

altheadx inc (IDGX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
President, Chief Operating Officer and Direct...
Total Annual Compensation: --
Co-Founder and Co-Chairperson of the Board
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

altheadx inc (IDGX) Key Developments

AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Cardiovascular Institute of the South to Adopt AltheaDx's IDgenetix Testing Services

AltheaDx announced an agreement with the Cardiovascular Institute of the South (CIS) to implement AltheaDx's IDgenetix testing portfolio within their system. The IDgenetix pharmacogenetic (PGx) testing portfolio enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions including cardiovascular disease, neuropsychiatric disorders, and pain. The IDgenetix testing portfolio will assist CIS in identifying optimal drugs for their patients as well as dosing guidelines based on a patient's genetic make-up, current prescription regimen and other key factors. IDgenetix is designed to enable healthcare providers to make timely and evidence-based decisions, reduce the overall cost of patient care by reducing adverse events, optimizing patients' overall therapeutic regimen and helping to achieve a faster therapeutic response.

AltheaDx, Inc. Announces Appointment Noah Nasser as Senior Vice President of Sales, Effective February 2, 2015

AltheaDx, Inc. announced the appointment of Noah Nasser as Senior Vice President of Sales, effective February 2, 2015. Mr. Nasser will report to Greg Hamilton, Chief Executive Officer of AltheaDx. Mr. Nasser brings more than 20 years of commercial and managerial experience within the diagnostic, medical device and life science fields. Prior to joining AltheaDx, Mr. Nasser was the Global Sales Leader for Verinata Health. As Vice President of Sales and Market Development at Verinata, Mr. Nasser was responsible for global commercialization of the verifi® prenatal test.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDGX:US $0.00 USD 0.00

IDGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDGX.
View Industry Companies
 

Industry Analysis

IDGX

Industry Average

Valuation IDGX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALTHEADX INC, please visit www.altheadx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.